Quarterly report [Sections 13 or 15(d)]

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

v3.25.3
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Costs and expenses:        
Research and development $ 7,649,697 $ 4,189,873 $ 23,434,243 $ 10,016,982
Selling, general and administrative 5,611,503 1,637,603 16,780,525 5,643,386
Change in fair value contingent consideration (492,827) 0 (2,016,111) 0
Total costs and expenses 12,768,373 5,827,476 38,198,657 15,660,368
Loss from operations (12,768,373) (5,827,476) (38,198,657) (15,660,368)
Interest income 838,093 49,410 2,674,119 273,059
Net loss (11,930,280) (5,778,066) (35,524,538) (15,387,309)
Other comprehensive income (loss), net of tax        
Unrealized gain (loss) on marketable securities (1,245) 2,778 33,059 877
Comprehensive loss $ (11,931,525) $ (5,775,288) $ (35,491,479) $ (15,386,432)
Net loss per share - basic $ (0.13) $ (0.65) $ (0.4) $ (2.03)
Net loss per share - diluted $ (0.13) $ (0.65) $ (0.4) $ (2.03)
Weighted-average number of shares outstanding basic 90,050,973 8,882,570 89,867,805 7,592,103
Weighted-average number of shares outstanding diluted 90,050,973 8,882,570 89,867,805 7,592,103